Navigation Links
CNA Finance Provides Research Update On Aytu Bioscience And Natesto®
Date:8/17/2017

CNA Finance Chief Research Analyst, Kenny Soulstring, today announced that the stock market news outlet had provided a research update on Aytu Bioscience and cited promising increases in the prescription rates for Natesto®, the company's nasally administered TRT product.

According to Soulstring, prescription rates for Natesto® have more than doubled since March of this year and on a sequential basis, month over month, Natesto® prescription rates have jumped to 593 for the month of June, Aytu's fourth consecutive month of increased prescription levels, representing an increase in excess of 100% during the prior four months.

According to Soulstring, he believes that shares of Aytu Bioscience are under undue pressure due to factors associated with its recent private placement, which provided warrant options as part of the package. In contrast to market sentiment, Soulstring believes that current price levels may offer a tremendous opportunity to purchase shares of Aytu at discounted prices.

Kenny Soulstring commented, "First and foremost, the company is now well capitalized and has ample cash for the next four quarters of business. Combined with the sharp increases in Natesto® prescription rates, the company may be on track to become a profitable company by the end of 2018." He added, "Investors that understand the market pressures from any dilutive financing also know that in many cases the market overshoots what a natural level of share decline should be, and I believe that is the case investors are witnessing for the current share price of Aytu Bioscience."

As noted in a detailed release by CNA Finance, sales of Natesto® have increased on a sequential basis for the previous four months, remains the ONLY available TRT product that does not require an FDA mandated Black Box warning, and has proven itself more effective and significantly safer than competing and available products on the market.

Soulstring also believes that once the momentum materializes for insurance reimbursement, sales of Natesto® have an opportunity to ramp significantly, and with its focused, and credentialed sales force may be in a position to capture at least 5% of the $2 billion market potential.

To view Kenny Soulstring's full analysis of Aytu Bioscience and Natesto®, click here.

Read the full story at http://www.prweb.com/releases/2017/08/prweb14597469.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. GlycoVaxyn AG secures CHF 5.1 million Strategic Translation Award from the Wellcome Trust to finance clinical development of Shigella vaccine
2. Benu BioVentures to Finance Early Biopharmaceutical Clinical Development
3. Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer
4. ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria
5. iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare
6. Neurotez Engages Invictus Global Capital as Corporate Finance & Capital Markets Advisors
7. Revenue Leak Soon Turns to Flood: Payment Penalties for High Infection Rates Draining Hospital Finances
8. Yew Bio-Pharm Group Signs Sales Agreement and Receives Subsidy Grant from the Finance Department of Heilongjiang Province, China
9. Oxford Finance Closes $20 Million Debt Facility with Inhibrx
10. Oxford Finance Provides $10 Million Debt Financing to Celula
11. CSM Appoints Michael Morse as Vice President of Finance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... ... October 09, 2017 , ... ... in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the ... in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available ... bioinformatics software to perform Hi-C metagenome deconvolution using their own facilities, supplementing ...
(Date:10/6/2017)... ... October 06, 2017 , ... The ... and technology sector at their fourth annual Conference where founders, investors, innovative practitioners ... and the ELEVATE pitch competition showcasing early stage digital health and med tech ...
(Date:10/5/2017)... ... October 05, 2017 , ... LabRoots , the leading provider of educational ... is giving back to cancer research with a month-long promotion supporting the advancement of ... 31, shoppers can use promo code PinkRibbon to get 10 percent off their purchase ...
Breaking Biology Technology:
(Date:4/13/2017)... PUNE, India , April 13, 2017 According ... Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication ... by MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 ... Annual Growth Rate (CAGR) of 17.3%. ... ...
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
Breaking Biology News(10 mins):